Back to top

gene-editing: Archive

Zacks Equity Research

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

RHHBYPositive Net Change JNJPositive Net Change MRKPositive Net Change SGENPositive Net Change

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected

CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.

JNJPositive Net Change VRTXPositive Net Change CRSPNegative Net Change CRBUPositive Net Change

Zacks Equity Research

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

NVSPositive Net Change RHHBYPositive Net Change JNJPositive Net Change SRPTNegative Net Change

Zacks Equity Research

Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View

Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.

NVSPositive Net Change JNJPositive Net Change VRTXPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

On Vertex's (VRTX) Q2 earnings call, investors focus will likely be on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

AZNPositive Net Change NVONegative Net Change VRTXPositive Net Change CRSPNegative Net Change